FibroGen, Inc. (FGEN)

Market Cap	22.67M
Revenue (ttm)	7.00M
Net Income (ttm)	-10.01M
Shares Out	4.04M
EPS (ttm)	-2.49
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	33,054
Open	5.58
Previous Close	5.25
Day's Range	5.48 - 5.73
52-Week Range	4.50 - 38.25
Beta	0.74
Analysts	Strong Buy
Price Target	250.00 (+4,356.33%)
Earnings Date	Aug 5, 2025

About FGEN

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. Its pipeline products include FG-3165 a...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 14, 2014
• Employees: 225
• Stock Exchange: NASDAQ
• Ticker Symbol: FGEN
• Website: https://www.fibrogen.com

Financial Performance

In 2024, FibroGen's revenue was $29.62 million, a decrease of -36.71% compared to the previous year's $46.80 million. Losses were -$47.58 million, -83.26% less than in 2023.

Analyst Summary

According to one analyst, the rating for FGEN stock is "Strong Buy" and the 12-month stock price target is $250.0.

Price Target

$250.0

(4,356.33% upside)

Analyst Consensus: Strong Buy